At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Celecoxib +2 moredrug
Likely dose
Celecoxib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis
In Brief
A Phase 2 clinical trial evaluating Celecoxib, Creatine, and 1 other intervention for Amyotrophic Lateral Sclerosis. Completed, enrolled 86 participants across 19 sites.
Detailed Summary
The objective of this study is to compare two combinations of drugs, minocycline and creatine or celecoxib and creatine, in a phase II trial designed to determine which combination is more effective for ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsALS Association, Pfizer
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedJul 2006
Study CompletionMay 2007
TodayJul 2026
First PostedJul 24, 2006
Enrollment StartJul 1, 2006
Study CompletionMay 1, 2007
TodayJul 2, 2026
Posted 19.9 years ago
Interventions
Celecoxibdrug
Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
Creatinedrug
10 g BID for either study arm
Minocyclinedrug
Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm